INCREASING EFFICIENCY OF VENTILATION IN COVID-19. The Alginate oligosaccharide OligoG CF-5/20 may be an immediate low risk trial Covid-19.

UPDATE: AUSTRALIAN DRUG TRIAL / AlgiPharma AS

Immediate available drug for Cystic Fibrosis could be utilized to save lives in Covid-19 crisis.The Alginate oligosaccharide OligoG CF-5/20 may be an immediate low risk trial Covid-19. It is a drug being tested for Cystic Fibrosis.
It is currently in Clinical Trials. Can this help in Ventilator Therapy and Decrease Deaths and Time on Ventilators?

Decreasing Mucous Build Up Should Decrease Need Of Respirators For Covid-19 Patients And Increase Survival Rates

THIS IS WORK BEING DONE IN AUSTRALIA!
John Hunter Hospital
Newcastle, New South Wales, Australia

There are also other Clinical Trials underway for Cystic Fibrosis. Should we consider these Orphan Drugs or Emergency drugs and consider immediate testing on patients?

* studies on PUBMED https://www.ncbi.nlm.nih.gov/pubmed/…

https://www.sleepandhealth.com/decreasing-mucous-build-dec…/

Leave a Reply

Your email address will not be published. Required fields are marked *